AWM
CRMD icon

Accredited Wealth Management’s CorMedix CRMD Stock Holding History

Accredited Wealth Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.82K Buy
+1,254
New +$15.2K ﹤0.01% 307

Other funds holding CRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Accredited Wealth Management's CRMD Position: Q3 2025 in Review

Accredited Wealth Management opened a new position in CorMedix (CRMD) in Q3 2025: 1,254 shares worth $5.82K. The stake represents ﹤0.01% of the portfolio and ranks #307 among its holdings.

190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

  • Accredited Wealth Management held 1,254 shares of CorMedix worth $5.82K as of Q3 2025.
  • CorMedix was a new Accredited Wealth Management position in Q3 2025.
  • CorMedix made up ﹤0.01% of Accredited Wealth Management's portfolio in Q3 2025, its #307 holding.
  • 190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on Accredited Wealth Management's 13F filing for Q3 2025, filed 12 Nov 2025.